Chief Executive Officer
The founding CEO of Darmiyan, Padideh is a 2020 Fortune 40 under 40 global healthcare leader/ influencer, and a 2018 TEDMED Hive Innovator who is listed by Healthcare Tech Report in Top 25 Women Leaders in Biotech for 2021. Under her leadership, Darmiyan raised seed funding led by Eisai, IT-Farm and Y-Combinator and secured US and Japanese patents for BrainSee, the predictive AI-Powered SaaS for Alzheimer’s disease diagnosis. She has been leading the Company for the past 5 years, taking the technology through multiple stages of development, from conception to a functioning product. Recently, FDA granted Darmiyan the breakthrough designation for BrainSee and this helped the company achieve widespread recognition in the biomedical and life science communities, including being a 2021 UCSF Health Awards finalist. In Persian Darmiyan means “in-between,” recognizing how the company’s technology decodes the space between our cells to illuminate the status of brain health, often before Alzheimer’s diagnosis.
Padideh is well-regarded globally for her geometrical modeling expertise, cross cultural understanding and visionary approach to complex problems. In Medscape, Psychology Today and elsewhere she has noted her commitment to inclusion and equality in our basic science studies, translational research, technology innovations and clinical trials. Prior to founding Darmiyan, she was an Adjunct Assistant Professor at New York University School of Medicine, where she previously completed three years of postdoctoral training in biophysical neuroscience, 2010-2013, under supervision of Professor Charles Nicholson, the pioneer of brain microstructure modeling. Padideh got her PhD in biological physics from Royal Institute of Technology (KTH) in Stockholm, Sweden in 2010. Her PhD thesis entitled, “Biophysical mechanisms underlying cellular homeostasis,” laid a foundation for the company’s novel work creating a virtual microscope of the brain. In her free time Padideh enjoys teaching Persian classical music.